Minimal side effects and short recovery time reported for dsuvia®-treated patients: plastic surgery podium presentation at the aesthetic meeting 2022

Hayward, calif. , april 25, 2022 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), ("acelrx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced a summary of results from a podium presentation on dsuvia® (sufentanil sublingual tablet (sst), 30 mcg) presented at the annual meeting of the aesthetic society®, "the aesthetic meeting 2022", held from april 20 -24 at the san diego convention center.
ACRX Ratings Summary
ACRX Quant Ranking